Definium Therapeutics US Inc.
- Address
- 1 World Trade Center Suite 8500
Sponsor Overview
Specializations
Psychiatry and anxiety disorders
Definium Therapeutics US Inc. is focused on clinical research in generalized anxiety disorder, with attention to symptom reduction and treatment response in adults living with persistent anxiety.
- Generalized anxiety disorder
- Anxiety symptom management
- Adult psychiatric care
The sponsor’s current clinical activity is centered on a single active program in GAD, reflecting a therapeutic interest in mental health conditions that affect daily functioning and emotional well-being.
Neuropsychiatric therapeutics
The research portfolio includes work on neuropsychiatric treatment approaches aimed at addressing anxiety-related distress through targeted clinical evaluation in a psychiatric population.
- Neuropsychiatric disorders
- Anxiety treatment
- Symptom relief
Clinical interest appears concentrated on interventions intended to improve anxiety outcomes in adults, with the sponsor operating across multiple active countries and collaborating research sites.
Central nervous system medicine
Definium Therapeutics US Inc. is engaged in research within central nervous system medicine, specifically in a condition where anxiety symptoms are a primary clinical concern.
- CNS-directed therapy
- Anxiety symptom burden
- Adult mental health
This focus places the sponsor within therapeutic development for disorders affecting cognition, mood, and stress-related functioning.
Placebo-controlled clinical evaluation in mental health
The sponsor’s trial activity is built around clinical assessment of treatment effect in mental health, with emphasis on comparing active intervention and placebo in anxiety disorder care.
- Clinical assessment of anxiety
- Comparative psychiatric research
- Therapeutic response evaluation
Its current research landscape is narrowly defined but clearly centered on advancing options for adults affected by chronic anxiety symptoms.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of the Efficacy and Safety of Lysergide (MM120) in Adults with Generalized Anxiety Disorder: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study |  Czechia France Germany Poland | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 0 are not being studied by other sponsors.
This sponsor has worked with 14 sites across their trial portfolio.
Therapeutic Focus
- 1.Mental Disorders1 trial150 other sponsors
Partnered Research Centres
14 centres- Address
- Sumavska 2, Vychodni Predmesti, 301 00 Pilsen
- Address
- 264 Rue Saint Pierre, 13005 Marseille
- Address
- Luisenring J 5, 68159 Mannheim
- Address
- 4 Rue Paul Eluard, 76300 Sotteville Les Rouen
- Address
- Ul. Na Zaspe 3, 80-546 Gdansk
- Address
- Hindenburgdamm 30, Lichterfelde, 12203 Berlin
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Definium Therapeutics US Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.